Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Hematol
Autori principali: Helbig, Grzegorz, Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Markiewicz, Mirosław, Kopera, Małgorzata, Zielińska, Patrycja, Woźniczka, Krzysztof, Kopińska, Anna, Grygoruk-Wiśniowska, Iwona, Koclęga, Anna
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6511342/
https://ncbi.nlm.nih.gov/pubmed/30919074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03679-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi